Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1977 2
1980 1
1981 4
1982 4
1983 4
1984 4
1985 2
1986 9
1987 6
1988 3
1989 7
1990 20
1991 10
1992 8
1993 5
1994 10
1995 6
1996 5
1997 9
1998 3
1999 5
2000 10
2001 10
2002 6
2003 14
2004 4
2005 12
2006 12
2007 20
2008 23
2009 18
2010 32
2011 38
2012 47
2013 42
2014 49
2015 48
2016 36
2017 31
2018 41
2019 34
2020 47
2021 63
2022 56
2023 53
2024 50
2025 34
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

871 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean s radvani (13 results)?
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Liu E, et al. N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607. N Engl J Med. 2020. PMID: 32023374 Free PMC article. Clinical Trial.
METHODS: In this phase 1 and 2 trial, we administered HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood to 11 patients with relapsed or refractory CD19-positive cancers (non-Hodgkin's lymphoma or chronic lymphocytic leukemia [CLL]). NK cells were transduced wit …
METHODS: In this phase 1 and 2 trial, we administered HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood to 11 patients with rela …
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency.
Biederstädt A, Basar R, Park JM, Uprety N, Shrestha R, Reyes Silva F, Dede M, Watts J, Acharya S, Xiong D, Liu B, Daher M, Rafei H, Banerjee P, Li P, Islam S, Fan H, Shanley M, Jin J, Kumar B, Woods V, Lin P, Tiberti S, Nunez Cortes AK, Jiang XR, Biederstädt I, Zhang P, Li Y, Rawal S, Liu E, Muniz-Feliciano L, Deyter GM, Shpall EJ, Fowlkes NW, Chen K, Rezvani K. Biederstädt A, et al. Cancer Cell. 2025 Nov 10;43(11):2069-2088.e11. doi: 10.1016/j.ccell.2025.07.021. Epub 2025 Aug 21. Cancer Cell. 2025. PMID: 40845844 Free PMC article.
Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma.
Kirschenbaum D, Xie K, Ingelfinger F, Katzenelenbogen Y, Abadie K, Look T, Sheban F, Phan TS, Li B, Zwicky P, Yofe I, David E, Mazuz K, Hou J, Chen Y, Shaim H, Shanley M, Becker S, Qian J, Colonna M, Ginhoux F, Rezvani K, Theis FJ, Yosef N, Weiss T, Weiner A, Amit I. Kirschenbaum D, et al. Cell. 2024 Jan 4;187(1):149-165.e23. doi: 10.1016/j.cell.2023.11.032. Epub 2023 Dec 21. Cell. 2024. PMID: 38134933 Free article.
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.
Shanley M, Daher M, Dou J, Li S, Basar R, Rafei H, Dede M, Gumin J, Pantaleόn Garcίa J, Nunez Cortes AK, He S, Jones CM, Acharya S, Fowlkes NW, Xiong D, Singh S, Shaim H, Hicks SC, Liu B, Jain A, Zaman MF, Miao Q, Li Y, Uprety N, Liu E, Muniz-Feliciano L, Deyter GM, Mohanty V, Zhang P, Evans SE, Shpall EJ, Lang FF, Chen K, Rezvani K. Shanley M, et al. Cancer Cell. 2024 Aug 12;42(8):1450-1466.e11. doi: 10.1016/j.ccell.2024.07.007. Cancer Cell. 2024. PMID: 39137729 Free PMC article.
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Marin D, et al. Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18. Nat Med. 2024. PMID: 38238616 Free PMC article. Clinical Trial.
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Liu E, et al. Leukemia. 2018 Feb;32(2):520-531. doi: 10.1038/leu.2017.226. Epub 2017 Jul 20. Leukemia. 2018. PMID: 28725044 Free PMC article.
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.
Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederstädt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani K. Li Y, et al. Nat Med. 2022 Oct;28(10):2133-2144. doi: 10.1038/s41591-022-02003-x. Epub 2022 Sep 29. Nat Med. 2022. PMID: 36175679 Free PMC article.
Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux.
Huang Y, Mohanty V, Dede M, Tsai K, Daher M, Li L, Rezvani K, Chen K. Huang Y, et al. Nat Commun. 2023 Aug 12;14(1):4883. doi: 10.1038/s41467-023-40457-w. Nat Commun. 2023. PMID: 37573313 Free PMC article.
Large-scale experiments using cell-lines, the cancer genome atlas (TCGA), and scRNA-seq data obtained from diverse cancer and immunotherapeutic contexts, including CAR-NK cell therapy, have validated METAFlux's capability to characterize metabolic heterogeneity and metabol …
Large-scale experiments using cell-lines, the cancer genome atlas (TCGA), and scRNA-seq data obtained from diverse cancer and immunotherapeu …
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells.
Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Shaim H, et al. J Clin Invest. 2021 Jul 15;131(14):e142116. doi: 10.1172/JCI142116. J Clin Invest. 2021. PMID: 34138753 Free PMC article.
871 results